论文部分内容阅读
生长因子受体家族通过与各种配体相互反应及家族成员间的相互作用介导细胞的信号转导 ,HER2属该家族成员 ,2 5 %～ 30 %的乳腺癌患者HER2过表达 ,而HER2过表达与肿瘤的侵袭性及不良预后有关。曲佐单抗 (trastuzumab)是第一个应用于治疗HER2过表达的乳腺癌患者的人源化单克隆抗体 ,临床试验结果表明 ,曲佐单抗对HER2过表达的乳腺癌患者有确切疗效。但是 ,抗HER2抗体的作用机制尚不十分清楚。本文综述了其有关研究进展 ,包括HER2表达下调、阻止HER2异二聚体形成、诱导G1期阻滞和p2 7表达、阻止HER2胞外区结构域的脱落和诱导机体免疫反应等抗体可能的作用机制
The growth factor receptor family mediates cell signaling through interactions with various ligands and family members, HER2 is a member of this family, and HER2 is overexpressed in 25% to 30% of breast cancer patients, while HER2 Overexpression and tumor invasion and poor prognosis. Trastuzumab is the first humanized monoclonal antibody to be used in the treatment of HER2 overexpressing breast cancer patients. The results of clinical trials indicate that trastuzumab is effective in patients with HER2 overexpressing breast cancer. However, the mechanism of action of the anti-HER2 antibody is not well understood. This review summarizes the possible role of antibodies such as the down-regulation of HER2 expression, the inhibition of HER2 heterodimer formation, the induction of G1 arrest and p27 expression, the loss of the extracellular domain of HER2, and the induction of an immune response in the body mechanism